JP2022535130A5 - - Google Patents
Info
- Publication number
- JP2022535130A5 JP2022535130A5 JP2021572298A JP2021572298A JP2022535130A5 JP 2022535130 A5 JP2022535130 A5 JP 2022535130A5 JP 2021572298 A JP2021572298 A JP 2021572298A JP 2021572298 A JP2021572298 A JP 2021572298A JP 2022535130 A5 JP2022535130 A5 JP 2022535130A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- polypeptide
- amino acid
- protein according
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025000023A JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857726P | 2019-06-05 | 2019-06-05 | |
| US62/857,726 | 2019-06-05 | ||
| PCT/US2020/036454 WO2020247843A2 (en) | 2019-06-05 | 2020-06-05 | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000023A Division JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535130A JP2022535130A (ja) | 2022-08-04 |
| JP2022535130A5 true JP2022535130A5 (https=) | 2023-06-13 |
| JP7778571B2 JP7778571B2 (ja) | 2025-12-02 |
Family
ID=73652315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572298A Active JP7778571B2 (ja) | 2019-06-05 | 2020-06-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
| JP2025000023A Pending JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000023A Pending JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220251202A1 (https=) |
| EP (1) | EP3980051A4 (https=) |
| JP (2) | JP7778571B2 (https=) |
| KR (1) | KR20220083660A (https=) |
| CN (1) | CN114786708A (https=) |
| AU (1) | AU2020287373B2 (https=) |
| CA (1) | CA3142738A1 (https=) |
| WO (1) | WO2020247843A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| US20230235005A1 (en) * | 2020-07-02 | 2023-07-27 | Inhibrx, Inc. | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| MX2023011964A (es) * | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4323392A4 (en) * | 2021-04-16 | 2025-03-19 | Orionis Biosciences, Inc. | IL-2-BASED CONSTRUCTS |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| EP4373854A1 (en) * | 2021-07-20 | 2024-05-29 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| EP4376870A4 (en) * | 2021-07-28 | 2025-07-23 | Anwita Biosciences Inc | INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| CA3238260A1 (en) * | 2021-11-17 | 2023-05-25 | John Thomas MULLIGAN | Compositions of protein complexes and methods of use thereof |
| CN116554344A (zh) * | 2022-01-30 | 2023-08-08 | 中国科学院生物物理研究所 | 一种pd1抗体与白介素2融合的双功能分子 |
| US20240076343A1 (en) * | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| EP4556493A1 (en) * | 2022-07-11 | 2025-05-21 | Genuv Inc. | Cytokine fusion protein |
| EP4605422A2 (en) * | 2022-10-20 | 2025-08-27 | Repertoire Immune Medicines, Inc. | Cd8 t cell targeted il2 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| US20250195677A1 (en) * | 2023-12-19 | 2025-06-19 | Cephalon Llc | Uses for attenuated il-2 immunoconjugates |
| TW202545980A (zh) * | 2024-02-01 | 2025-12-01 | 瑞典商阿斯特捷利康公司 | Ｃｄ８結合細胞介素銜接器及其使用方法 |
| CN118373896B (zh) * | 2024-04-19 | 2025-07-29 | 上海科棋药业科技有限公司 | 抗pd-1抗体与il-2突变体的双功能融合蛋白 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| JP5764127B2 (ja) * | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| AU2016304794B2 (en) * | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| MY201482A (en) * | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| CN110505883A (zh) * | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
| US10676516B2 (en) * | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| CN111511763B (zh) | 2017-08-09 | 2024-05-31 | 奥里尼斯生物科学有限公司 | Cd8结合剂 |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| KR20230112632A (ko) * | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
-
2020
- 2020-06-05 EP EP20819187.4A patent/EP3980051A4/en active Pending
- 2020-06-05 US US17/616,157 patent/US20220251202A1/en active Pending
- 2020-06-05 WO PCT/US2020/036454 patent/WO2020247843A2/en not_active Ceased
- 2020-06-05 CN CN202080051337.9A patent/CN114786708A/zh active Pending
- 2020-06-05 KR KR1020227000163A patent/KR20220083660A/ko active Pending
- 2020-06-05 CA CA3142738A patent/CA3142738A1/en active Pending
- 2020-06-05 JP JP2021572298A patent/JP7778571B2/ja active Active
- 2020-06-05 AU AU2020287373A patent/AU2020287373B2/en active Active
-
2025
- 2025-01-05 JP JP2025000023A patent/JP2025060983A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535130A5 (https=) | ||
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| AU2018298881B2 (en) | Improved dual specificity polypeptide molecule | |
| JP2025060983A (ja) | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 | |
| JP6464255B2 (ja) | 二重特異性ｔ細胞活性化抗原結合分子 | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| CN110382539B (zh) | 用于cd16a定向的nk细胞结合的串联双抗体 | |
| JP2023548045A5 (https=) | ||
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| KR20200143436A (ko) | Nk 세포 결합 항체 융합 구조체 | |
| JP2019533444A (ja) | ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質 | |
| EP3781597A1 (en) | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains | |
| RS56879B1 (sr) | Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija | |
| RS59992B1 (sr) | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije specifični za cd3 i cea | |
| CA3205670A1 (en) | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 | |
| CA3147677A1 (en) | Engineered interleukin-2 receptor beta agonists | |
| JP2024508949A (ja) | Ｐｄ－１標的化ｉｌ－２変異体イムノコンジュゲートとｆａｐ／４－１ｂｂ結合分子との併用療法 | |
| JP2024512382A (ja) | Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法 | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| KR20260062933A (ko) | 항-γδ TCR 항체 및 이의 용도 | |
| WO2025167357A1 (zh) | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 | |
| CN121752599A (zh) | 抗γδTCR抗体及其用途 | |
| Muller et al. | Diabodies, Single-Chain Diabodies, and Their Derivatives |